Literature DB >> 2367317

Disposition and metabolic profiling of the penetration enhancer Azone. I. In vitro studies: urinary profiles of hamster, rat, monkey, and man.

J W Wiechers1, B F Drenth, F A Adolfsen, L Prins, R A de Zeeuw.   

Abstract

Chain-labeled 14C-Azone was intravenously administered to hamster, monkey, and rat, to compare its metabolic profile with that obtained previously in humans after dermal application. Azone-derived radioactivity was excreted predominantly in the urine for both hamster and monkey, which is similar to the disposition in humans. Metabolic profiling in urine revealed extensive systemic metabolism to occur in all species studied. The main fraction of the metabolites was most polar in man, followed by rat, monkey, and hamster. Traces of the parent compound were detectable only in hamster urine. Although some of the polar major human metabolites were also present in rat urine, the animals were unsuitable for collecting metabolites of Azone observed in humans. In rats, complete cleavage of the dodecyl side chain was ruled out by administering Azone that had been labeled at two distinct positions of the molecule. Additionally, oral administration of Azone to rats resulted in the same metabolic profile as intravenous administration, indicating that gastrointestinal metabolism does not occur or is similar to systemic metabolism.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2367317     DOI: 10.1023/a:1015864632474

Source DB:  PubMed          Journal:  Pharm Res        ISSN: 0724-8741            Impact factor:   4.200


  8 in total

1.  The metabolic fate of the dopamine agonist 2-(N-propyl-N-2-thienylethylamino)-5-hydroxytetralin in rats after intravenous and oral administration. I. Disposition and metabolic profiling.

Authors:  T K Gerding; B F Drenth; H J Roosenstein; R A de Zeeuw; P G Tepper; A S Horn
Journal:  Xenobiotica       Date:  1990-05       Impact factor: 1.908

2.  Percutaneous absorption and elimination of the penetration enhancer Azone in humans.

Authors:  J W Wiechers; B F Drenth; J H Jonkman; R A de Zeeuw
Journal:  Pharm Res       Date:  1987-12       Impact factor: 4.200

3.  Percutaneous and systemic disposition of hexamethylene lauramide and its penetration enhancement effect on hydrocortisone in a rat sandwich skin-flap model.

Authors:  D D Tang-Liu; J Neff; H Zolezio; R Sandri
Journal:  Pharm Res       Date:  1988-08       Impact factor: 4.200

4.  Enhanced percutaneous penetration with 1-dodecylazacycloheptan-2-one.

Authors:  R B Stoughton
Journal:  Arch Dermatol       Date:  1982-07

5.  Influence of 1-dodecylazacycloheptan-2-one (Azone) on the topical therapy of cutaneous herpes simplex virus type 1 infection in hairless mice with 2',3'-di-O-acetyl-9-beta-D-arabinofuranosyladenine and 5'-O-valeryl-9-beta-D-arabinofuranosyladenine.

Authors:  W M Shannon; L Westbrook; W I Higuchi; K Sugibayashi; D C Baker; S D Kumar; J L Fox; G L Flynn; N F Ho; R Vaidyanathan
Journal:  J Pharm Sci       Date:  1985-11       Impact factor: 3.534

6.  Percutaneous absorption, metabolic profiling, and excretion of the penetration enhancer azone after multiple dosing of an azone-containing triamcinolone acetonide cream in humans.

Authors:  J W Wiechers; B F Drenth; J H Jonkman; R A de Zeeuw
Journal:  J Pharm Sci       Date:  1990-02       Impact factor: 3.534

7.  Concentration-dependent enhancement of 1-dodecylazacycloheptan-2-one on the percutaneous penetration kinetics of triamcinolone acetonide.

Authors:  D S Chow; I Kaka; T I Wang
Journal:  J Pharm Sci       Date:  1984-12       Impact factor: 3.534

8.  Influence of 1-dodecylhexahydro-2H-azepin-2-one (Azone) on the in vitro permeation of verapamil hydrochloride across rat, hairless mouse, and human cadaver skin.

Authors:  P Agrawala; W A Ritschel
Journal:  J Pharm Sci       Date:  1988-09       Impact factor: 3.534

  8 in total
  1 in total

Review 1.  Chemical enhancers for transdermal drug transport.

Authors:  K Bauerová; D Matusová; Z Kassai
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2001 Jan-Jun       Impact factor: 2.441

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.